bluuebunny/crossref_metadata_2025_split huggingface dataset:
Hodgkin's lymphoma presenting with heart failure: a case report
Authors: Amirimoghaddam Zeinab , Khoddami Malihe , Nayeri Nahid Dehghan , Molaee Somayeh 
Published: January 2010

Abstract

Introduction
Cardiac involvement in malignant lymphoma is one of the least investigated subjects in oncology. This article reports a case of cardiac involvement in Hodgkin's lymphoma which presented as heart failure.

Case presentation
We report the case of an 8-year-old Afghan girl with Hodgkin's lymphoma. The disease presented with systemic signs and symptoms, including abdominal distension, weakness, pallor, chills, fever, generalized edema, hepatosplenomegaly and generalized lymphadenopathy, as well as signs of heart failure. Test results showed a rare form of heart metastasis.

Conclusion
We report a case of Hodgkin's lymphoma with metastasis to the heart, detected premortem. Although the involvement of the heart in a malignancy is relatively common, premortem detection is unusual and only few studies have reported it in the literature.
Carcinoid tumor of the verumontanum (colliculus seminalis) of the prostatic urethra with a coexisting prostatic adenocarcinoma: a case report
Authors: Smith Maxwell , Lucia M Scott , Werahera Priya N , La Rosa Francisco G 
Published: January 2010

Abstract

Introduction
Urethral carcinoid tumors are very rare tumors with only four cases described in the literature.

Case presentation
We present the case of a 61-year-old man with a primary carcinoid tumor of the verumontanum (colliculis seminalis) portion of the prostatic urethra with a coexisting prostatic adenocarcinoma. In addition to whole mount hematoxylin and eosin staining, special immunoperoxidase staining specific for chromogranin A, neuron specific enolase, synaptophysin, pan-cytokeratin and PSA, and a special combined staining for racemase (α-methyl CoA) antigen and p63 antigen were performed. A review of the literature is included.
A single focus of invasive prostatic adenocarcinoma was identified in the periphery of the mid-left, posterior quadrant of the prostate. Approximately 17 mm from this adenocarcinoma, within the verumontanum of the prostatic urethra, there was a 3 mm maximal dimension carcinoid tumor.

Conclusion
Based on different histological features and antigenic profiles, we concluded that the two tumors were distinct.
Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report
Authors: Seo Yu Ri , Kim Se Hyung , Kim Hyun Jung , Kim Chan Kyu , Park Seong Kyu , Koh Eun Suk , Hong Dae Sik 
Published: January 2010

Abstract
No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old male patient with urothelial cancer (transitional cell carcinoma) in the right kidney underwent three rounds of adjuvant gemcitabine-cisplatin chemotherapy after extensive radical nephrectomy. However, he had new liver, lung metastases and synchronous two separate primary colon cancer. The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB). Liver and lung metastasis lesions disappeared after the 4th cycle of FOLFOX4 chemotherapy. In addition, colon cancer also disappeared after the 8th cycle of FOLFOX4 chemotherapy. The patient was still showing a complete response after 4 months. Clinical trials using the FOLFOX regimen as salvage therapy for gemcitabine-refractory advanced urothelial cancer are warranted.
Integration of HIV/AIDS services into African primary health care: lessons learned for health system strengthening in Mozambique ‐ a case study
Authors: Pfeiffer James , Montoya Pablo , Baptista Alberto J , Karagianis Marina , Pugas Marilia de Morais , Micek Mark , Johnson Wendy , Sherr Kenneth , Gimbel Sarah , Baird Shelagh , Lambdin Barrot , Gloyd Stephen 
Published: January 2010

IntroductionIn 2004, Mozambique, supported by large increases in international disease‐specific funding, initiated a national rapid scale‐up of antiretroviral treatment (ART) and HIV care through a vertical “Day Hospital” approach. Though this model showed substantial increases in people receiving treatment, it diverted scarce resources away from the primary health care (PHC) system. In 2005, the Ministry of Health (MOH) began an effort to use HIV/AIDS treatment and care resources as a means to strengthen their PHC system. The MOH worked closely with a number of NGOs to integrate HIV programs more effectively into existing public‐sector PHC services.Case DescriptionIn 2005, the Ministry of Health and Health Alliance International initiated an effort in two provinces to integrate ART into the existing primary health care system through health units distributed across 23 districts. Integration included: a) placing ART services in existing units; b) retraining existing workers; c) strengthening laboratories, testing, and referral linkages; e) expanding testing in TB wards; f) integrating HIV and antenatal services; and g) improving district‐level management. Discussion: By 2008, treatment was available in nearly 67 health facilities in 23 districts. Nearly 30,000 adults were on ART. Over 80,000 enrolled in the HIV/AIDS program. Loss to follow‐up from antenatal and TB testing to ART services has declined from 70% to less than 10% in many integrated sites. Average time from HIV testing to ART initiation is significantly faster and adherence to ART is better in smaller peripheral clinics than in vertical day hospitals. Integration has also improved other non‐HIV aspects of primary health care.ConclusionThe integration approach enables the public sector PHC system to test more patients for HIV, place more patients on ART more quickly and efficiently, reduce loss‐to‐follow‐up, and achieve greater geographic HIV care coverage compared to the vertical model. Through the integration process, HIV resources have been used to rehabilitate PHC infrastructure (including laboratories and pharmacies), strengthen supervision, fill workforce gaps, and improve patient flow between services and facilities in ways that can benefit all programs. Using aid resources to integrate and better link HIV care with existing services can strengthen wider PHC systems.
Nodal-Stage Classification in Invasive Lobular Breast Carcinoma: Influence of Different Interpretations of the pTNM Classification
Authors: van Deurzen Carolien H.M. , Cserni Gabor , Bianchi Simonetta , Vezzosi Vania , Arisio Riccardo , Wesseling Jelle , Asslaber Martin , Foschini Maria P. , Sapino Anna , Castellano Isabella , Callagy Grace , Faverly Daniel , Martin-Martinez Maria-Dolores , Quinn Cecily , Amendoeira Isabel , Kulka Janina , Reiner-Concin Angelika , Cordoba Alicia , Seldenrijk Cornelis A. , van Diest Paul J. 
Published: January 2010

Purpose Application of current nodal status classification is complicated in lobular breast carcinoma metastases. The aim of this study was to define the optimal interpretation of the pTNM classification in sentinel node (SN) –positive patients to select patients with limited or with a high risk of non-SN involvement. Patients and Methods SN metastases of 392 patients with lobular breast carcinoma were reclassified according to interpretations of the European Working Group for Breast Screening Pathology (EWGBSP) and guidelines by Turner et al, and the predictive power for non-SN involvement was assessed. Results Reclassification according to definitions of EWGBSP and Turner et al resulted in different pN classification in 73 patients (19%). The rate of non-SN involvement in the 40 patients with isolated tumor cells according to Turner et al and with micrometastases according to EWGBSP was 20%, which is comparable to the established rate for micrometastases. The rate of non-SN involvement in the 29 patients with micrometastases according to Turner et al and with macrometastases according to EWGBSP was 48%, which is comparable to the established rate for macrometastases. Therefore, the EWGBSP method to classify SN tumor load better reflected the risk of non-SN involvement than the Turner et al system. Conclusion Compared with the guidelines by Turner et al, the EWGBSP definitions better reflect SN metastatic tumor load and allow better differentiation between patients with lobular breast carcinoma who have a limited or a high risk of non-SN metastases. Therefore, we suggest using the EWGBSP definitions in these patients to select high-risk patients who may benefit from additional local and/or systemic therapy.
Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
Authors: Dahlberg Suzanne E. , Sandler Alan B. , Brahmer Julie R. , Schiller Joan H. , Johnson David H. 
Published: January 2010

PurposeBevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) with demonstrated efficacy in combination with carboplatin and paclitaxel (PCB) for the treatment of advanced non–small-cell lung cancer (NSCLC). Administration of bevacizumab is postulated to decrease nitric oxide synthesis and lead to hypertension, which may be a physiological sign that the VEGF pathway is more actively being blocked and could result in improved outcomes.Patients and MethodsEastern Cooperative Oncology Group (ECOG) 4599 randomly assigned patients with nonsquamous NSCLC to carboplatin and paclitaxel (PC) versus PCB. Hypertensive patients were compared with nonhypertensive patients with respect to overall survival (OS) and progression-free survival (PFS) using blood pressure data and adverse event data separately. High blood pressure (HBP) by the end of cycle 1 was defined as blood pressure > 150/100 at any previous time or at least a 20-mmHg increase in diastolic blood pressure from baseline.ResultsIn a multivariable Cox model adjusting for HBP as a time-varying covariate, comparing those on PCB with HBP with those on PC gave an OS hazard ratio (HR) of 0.60 (95% CI, 0.43 to 0.81; P = .001); comparing those on PCB without HBP with those on PC alone, the OS HR was 0.86 (95% CI, 0.74 to 1.00; P = .05). Comparing the PCB HBP group with PC gave an adjusted PFS HR of 0.54 (95% CI, 0.41 to 0.73; P < .0001) and comparing those on PCB without HBP to those on PC, the HR was 0.72 (95% CI, 0.62 to 0.84; P < .0001). The 6-month cumulative incidence of hypertension was 6.2% (95% CI, 3.9% to 8.6%).ConclusionData from ECOG 4599 suggest that onset of HBP during treatment with PCB may be associated with improved outcomes, and additional studies of the downstream effects of VEGF suppression and hypertension are needed.
Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
Authors: Evens Andrew M. , David Kevin A. , Helenowski Irene , Nelson Beverly , Kaufman Dixon , Kircher Sheetal M. , Gimelfarb Alla , Hattersley Elise , Mauro Lauren A. , Jovanovic Borko , Chadburn Amy , Stiff Patrick , Winter Jane N. , Mehta Jayesh , Van Besien Koen , Gregory Stephanie , Gordon Leo I. , Shammo Jamile M. , Smith Scott E. , Smith Sonali M. 
Published: January 2010

PurposeAdult post-transplantation lymphoproliferative disease (PTLD) has a reported 3-year overall survival (OS) of 35% to 40%. The impact of rituximab on the outcome of PTLD is not well defined.MethodsWe examined the clinical features and outcomes among a large cohort of solid organ transplantation (SOT) –related patients with PTLD who were recently treated at four Chicago institutions (from January 1998 to January 2008).ResultsEighty patients with PTLD were identified who had a median SOT-to-PTLD time of 48 months (range, 1 to 216 months). All patients had reduction of immunosuppression as part of initial therapy, whereas 59 (74%) of 80 patients received concurrent first-line rituximab with or without chemotherapy. During 40-month median follow-up, 3-year progression-free survival (PFS) for all patients was 57%, and the 3-year overall survival (OS) rate was 62%. Patients who received rituximab-based therapy as part of initial treatment had 3-year PFS of 70% and OS 73% compared with 21% (P < .0001) and 33% (P = .0001), respectively, without rituximab. Notably, of all relapses, only 9% (4 of 34 patients) occurred beyond 12 months from PTLD diagnosis. On multivariate regression analysis, three factors were associated with progression and survival: CNS involvement (PFS, 4.70; P = .01; OS, 3.61; P = .04), bone marrow involvement (PFS, 2.95; P = .03; OS, 3.14; P = .03), and hypoalbuminemia (PFS, 2.96; P = .05; OS, 3.64; P = .04). Furthermore, a survival model by multivariate CART analysis that was based on number of adverse factors present (ie, 0, 1, ≥ 2) was formed: 3-year PFS rates were 84%, 66%, 7%, respectively, and 3-year OS rates were 93%, 68%, 11%, respectively (P < .0001).ConclusionThis large, multicenter, retrospective analysis suggests significantly improved PFS and OS associated with early rituximab-based treatment in PTLD. In addition, clinical factors at diagnosis identified patients with markedly divergent outcomes.
Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer
Authors: Blasberg Justin D. , Pass Harvey I. , Goparaju Chandra M. , Flores Raja M. , Lee Suzie , Donington Jessica S. 
Published: January 2010

PurposePlasma osteopontin (OPN) levels in advanced non–small-cell lung cancer (NSCLC) correlate with therapeutic response and survival, but the utility of plasma OPN for diagnosis and monitoring of early-stage NSCLC has not been investigated. We hypothesize that plasma OPN levels are elevated in early-stage NSCLC and decrease with resection.Patients and MethodsPresurgery plasma OPN levels (in ng/mL) were measured by enzyme-linked immunosorbent assay (ELISA) in a discovery set of 60 patients with early-stage NSCLC and were compared with data from 56 cancer-free smokers. Presurgery OPN was validated in an independent cohort of 96 patients with resectable NSCLC. The presurgery levels in the latter cohort were compared with matched postsurgery levels. Perioperative OPN levels were correlated with demographics, tumor characteristics, and perioperative events. OPN was monitored during follow-up.ResultsDiscovery set presurgery NSCLC OPN (271 ± 31 ng/mL) was higher than smokers (40 ± 2 ng/mL; P = .001). Presurgery OPN was similar in the NSCLC validation cohort (324 ng/mL ± 20 ng/mL; P = .134). Postsurgery OPN (256 ng/mL ± 21 ng/mL) measured at mean of 9.8 weeks (range, 2 to 46 weeks) was lower than presurgery OPN (P = .005). Time from surgery significantly impacted postsurgery OPN: OPN ≤ 6 weeks postsurgery (303 n/mL ± 26 ng/mL) was higher than OPN greater than 6 weeks postsurgery (177 ng/mL ± 29 ng/mL; P = .003). Multivariate analysis noted correlations between albumin and creatinine to presurgery OPN and use of thoracotomy to postsurgery OPN. Recurrence rate was 5% at 29 weeks mean follow-up. OPN at recurrence was elevated from postsurgery nadir.ConclusionPlasma OPN levels are elevated in early-stage NSCLC. They are reduced after resection and appear to increase with recurrence. Plasma OPN may have utility as a biomarker in early-stage NSCLC.
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Authors: Ludwig Heinz , Beksac Meral , Bladé Joan , Boccadoro Mario , Cavenagh Jamie , Cavo Michele , Dimopoulos Meletios , Drach Johannes , Einsele Hermann , Facon Thierry , Goldschmidt Hartmut , Harousseau Jean-Luc , Hess Urs , Ketterer Nicolas , Kropff Martin , Mendeleeva Larisa , Morgan Gareth , Palumbo Antonio , Plesner Torben , San Miguel Jesús , Shpilberg Ofer , Sondergeld Pia , Sonneveld Pieter , Zweegman Sonja 
Published: January 2010

Abstract
The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents thalidomide, bortezomib, and lenalidomide has expanded treatment options and has improved the outcome of patients with MM. Following the introduction of these agents in the relapsed/refractory setting, they are also undergoing investigation in the initial treatment of MM. A number of phase III trials have demonstrated the efficacy of novel agent combinations in the transplant and nontransplant settings, and based on these results standard induction regimens are being challenged and replaced. In the transplant setting, a number of newer induction regimens are now available that have been shown to be superior to the vincristine, doxorubicin, and dexamethasone regimen. Similarly, in the front-line treatment of patients not eligible for transplantation, regimens incorporating novel agents have been found to be superior to the traditional melphalan plus prednisone regimen. Importantly, some of the novel agents appear to be active in patients with high-risk disease, such as adverse cytogenetic features, and certain comorbidities, such as renal impairment. This review presents an overview of the most recent data with these novel agents and summarizes European treatment practices incorporating the novel agents.
In-Situ Combustion : Opportunities and Anxieties
Authors: Dayal Har Sharad , Bhushan B. V. , Mitra Sujit , Sinha S. K. , Sur Sidhartha 
Published: January 2010

Abstract
To enhance production and improve recovery, normal wet In Situ Combustion (ISC) process has been applied by ONGC in the heavy oil field of Balol situated in the state of Gujarat, India. Injection of air @ 0.7 MMSm3/d resulted in increasing oil production from the field from 350m3/d to about 700 m3/d with corresponding reduction in average water cut from 80% to 55%. The field results indicate that the process is not archaic and has the strength to arrest strong edge water encroachment. It can significantly increase production and recovery, if applied in right perspective. The process needs to be looked upon as a displacement process also rather than a conventional thermal technique only. The process presents significant opportunities in conventional and heavy oil reservoirs to add reserves. The air compressors and well completions are the anxieties that can be mitigated by adopting good engineering based on an informed understanding of the process. The ISC process never looses spark, provided it is designed and operated in high temperature oxidation mode.
Management of Change, Key Component of an Effective HSE Management System
Authors: Julaihi Saiee , Jaafar Ahmad Tarmizi , Abu Bakar Nur Atikah 
Published: January 2010

Abstract
Management of Change System is an essential component of HSE management. Whilst the typical risk management framework is aimed at ensuring a safe system of work, the somewhat complementary management of change system is crucial in sustaining that safe system of work.
In the execution of work activities, changes or deviation from defined processes/procedures is inevitable; and this is not necessarily a problem provided such changes are adequately controlled. The key consideration in managing changes is ensuring that risk posed by proposed changes, if any, remains ALARP.
In PETRONAS Carigali, the management of change system clearly defines the required change governance, spanning the entire value chain of the company business; it caters for:
▪ Geophysical (survey and seismic) activities ▪ drilling activities ▪ facility design, fabrication and installation ▪ production and maintenance activities ▪ facility abandonment and decommissioning
Key considerations in the management of change system include the followings:
▪ Types of changes requiring control are clearly defined; including changes to plant design, operating philosophy, plant equipment, operating parameters, standard operating procedures, personnel, bypass of safety critical equipment, etc. ▪ For temporary changes, the maximum duration and criteria for approval of such changes clearly defined. ▪ Types of risk assessment that need to be carried out for the various proposed changes; including aspect of risk screening and acceptance criteria. ▪ Approval process, including review by multi-disciplines technical authorities. ▪ Key performance indicators and target; the critical success factors of the management of change system.
Specific examples of changes, selected from amongst the different types of changes representing the entire business value chain, will be discussed. This is aimed at sharing PETRONAS Carigali experience on how changes are managed in the organization, including a perspective of the key challenges.
Process Wastewater Treatment and Management in Gas-to-Liquids Industries
Authors: Pon Saravanan N. , Van Vuuren Marlene J. 
Published: January 2010

Abstract
Gas to Liquids, or GTL, is a technology breakthrough to convert natural gas into high-performing, ultra-clean liquid fuels by means of Fischer-Tropsch (FT) reaction. A by-product of the FT reaction is process wastewater, generated in large volumes, 25% more than hydrocarbon products, on a weight basis. The process wastewater generated from GTL industries needs to be treated to comply with the standards set by Regulatory Agencies for effective reuse as well as for safe discharge into the sea or other water bodies. The treatment and management of wastewater for reuse and disposal is particularly important for Gulf countries, since they occupy one of the most arid regions in the world. This paper addresses treatment methodology for GTL process wastewater and the management of treated wastewater, including approaches to their reuse and alternate disposal options.
The first part of this paper identifies source of wastewater from the GTL industries and briefly describes typical contaminants found in process wastewater and extensively illustrates treatment technology. Process wastewater mainly contains dissolved hydrocarbons and acidic contaminants, such as, alcohols, acids, ketones, aldehydes, acetates and other oxygenates. The second part discusses the management of treated water for various applications and how they are reused or alternatively disposed off. In addition a number of recommendations, emphasizing in particular that more efforts are needed in GTL industries for the improvement of water reuse through an integrated, multi-disciplinary water management strategy.